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Purpose
To determine the inflammatory changes in the airways of
allergic pediatric asthma patients treated with omalizu-
mab, measured by the percentage of eosinophil in induced
sputum and exhaled nitric oxide.
Methods
From 2006 to 2012, 31 patients with asthma were treated
with omalizumab (15 male -51.6%; 16 females -48,4%).
Age ranged between 6 -18 years. The dose of omalizumab
was calculated according to the dosing table of the
company. Omalizumab was administered subcutaneously
in the hospital.
Protocol
Baseline analysis from every patient: Total IgE concentra-
tion, specific IgE against the relevant allergen, the percen-
tage of eosinophils in a smear of induced sputum and the
exhaled fraction of nitric oxide (NO). Induced sputum and
NO were measured at the end of follow-up. Data are
shown as mean (SEM). A Student t-test for paired data
was used for comparison.
Results
Follow-up of patients was not uniform, ranging from 2-6
years. Total IgE concentration at entry: 668.89 (117.79)
IU/mL; Specific IgE against the major antigen at entry:
42.15 (7.32) IU/mL; ( 22 house dust mite; 7 alternaria;
2 cladosporium). Initial and end induced sputum: 6.26
(2.03)% vs 2.47 (0.36)% ; (p<0.05). Initial and end NO
values: 19.04 (1.98) ppb vs 18.10 (2.11) ppb (p=NS).Three
patients were excluded from the evaluation due to exager-
ated values in final NO measurement that preceded a
severe exacerbation.
Conclusions
Omalizumab allowed a statistically significant decrease in
the percentage of eosinophils in induced sputum of this
cohort of patients. Although very sensible, NO is a less
reproducible and thus less reliable method to evaluate
chronic airway inflammation in a pediatric allergic popula-
tion with uncontrolled severe asthma. Induced sputum
seems to be a better method to monitor chronic inflam-
mation and thus the response to chronic omalizumab
treatment while NO measurement would be more useful
to monitor acute events preceding exacerbations.
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